Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence
Journal of Molecular Pathology · 01.07.2026 · 7 (3) · 25
DOI: 10.3390/jmp7030025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Pathology, online erschienen am 01.07.2026. Verfasst von Roopeessh Vempati und 12 weiteren Autor:innen. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia and is increasingly driven by cardiometabolic disease, including type 2 diabetes mellitus (T2DM), obesity, and insulin resistance. These conditions promote atrial electrical instability and a permissive substrate through mitochondrial dysfunction, oxidative stress, inflammation, calcium-handling abnormalities, and profibrotic signaling, culminating in atrial fibrosis and conduction heterogeneity. Metformin, the foundational glucose-lowering therapy for T2DM, exerts pleiotropic actions that intersect with these upstream pathways. Beyond glycemic control, metformin induces mild mitochondrial complex I modulation with reduction of reverse electron transfer-derived reactive oxygen species, activates adenosine monophosphate (AMP) activated protein kinase, and attenuates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated cytokine signaling; experimental data further suggest favorable effects on adiponectin–sarcoendoplasmic reticulum calcium adenosine triphosphatase (SERCA) 2a-dependent calcium cycling, connexin expression, small-conductance Ca2+-activated K+ channel remodeling, lipid handling, and transforming growth factor-β (TGF)-β-associated fibrotic remodeling. Observational cohort studies have reported associations between metformin exposure and a modest reduction in incident AF, particularly with longer treatment duration and in higher-risk metabolic phenotypes; device-based surveillance cohorts support a preventive association for new-onset AF rather than reduction of established AF burden. Data after catheter ablation suggest improved freedom from recurrence in metformin-treated patients, whereas evidence in postoperative AF is largely neutral, likely reflecting distinct acute mechanisms. Collectively, metformin may be best conceptualized as a potential substrate-modifying, upstream therapy candidate; however, confounding, exposure misclassification, and heterogeneity in comparators limit causal inference, underscoring the need for prospective randomized trials with AF endpoints. In practice, integration with comprehensive risk-factor modification (blood pressure, weight, sleep apnea, and glycemic optimization) remains essential when considering AF prevention strategies.
Zitieren
APA
Vempati, R., Gahona, C. T., Haddad, F., Manickavelan, H. V., Zakaria, F., Hanna, J., Sanusi, M., Bhatt, P., Haddad, R., Mohammed, F., Mylavarapu, M., Reddy, Y. M., & Nair, R. (2026). Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence. Journal of Molecular Pathology, 7(3), 25. https://doi.org/10.3390/jmp7030025
Vancouver
Vempati R, Gahona CT, Haddad F, Manickavelan HV, Zakaria F, Hanna J, et al. Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence. Journal of Molecular Pathology. 2026;7(3):25. doi:10.3390/jmp7030025
BibTeX
@article{Vempati2026,
author = {Vempati, Roopeessh and Gahona, Christian Toquica and Haddad, Fadi and Manickavelan, Hari Vorappan and Zakaria, Faiza and Hanna, Julia and Sanusi, Muhammad and Bhatt, Parjanya and Haddad, Rana and Mohammed, Fawaz and Mylavarapu, Maneeth and Reddy, Yeruva Madhu and Nair, Rajiv},
title = {Metformin as an Upstream Substrate-Modifying Strategy for Atrial Fibrillation in Metabolic Dysfunction: Mechanistic Rationale and Clinical Evidence},
journal = {Journal of Molecular Pathology},
year = {2026},
volume = {7},
number = {3},
pages = {25},
doi = {10.3390/jmp7030025}
}
EUVIMED